Contains Solid Synthetic Resin Patents (Class 424/501)
-
Patent number: 11369631Abstract: A gelling liquid formulation comprising a thermoresponsive hydrogel modified with an agent that reduces the alters the native gelation point of the thermoresponsive hydrogel and methods for making and using the same.Type: GrantFiled: April 3, 2020Date of Patent: June 28, 2022Assignee: UMM Rainforest InnovationsInventors: Jason Thomas McConville, Elnaz Sadeghi
-
Patent number: 11305013Abstract: The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.Type: GrantFiled: August 25, 2015Date of Patent: April 19, 2022Assignees: Drexel University, Thomas Jefferson UniversityInventors: John Robert Eisenbrey, Margaret Alison Wheatley, Patrick O'Kane, Lorenzo Albala, Flemming Forsberg
-
Patent number: 11279933Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.Type: GrantFiled: April 7, 2020Date of Patent: March 22, 2022Assignee: Stichting Radboud universitair medisch centrumInventors: Robert Wilhelmus Johanna Collin, Franciscus Peter Maria Cremers, Antonia Ingrid Den Hollander
-
Patent number: 11253480Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent is a histone deactylase inhibitor.Type: GrantFiled: October 30, 2018Date of Patent: February 22, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Steven R. Little, Michelle L. Ratay
-
Patent number: 11253598Abstract: Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate.Type: GrantFiled: September 12, 2016Date of Patent: February 22, 2022Inventors: Hye Yeong Nam, Bong-Oh Kim, Min-Hyo Seo, Ji-Yeon Son, Ji-Hye Choi, Sang Hoon Kim
-
Patent number: 11246879Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.Type: GrantFiled: February 9, 2017Date of Patent: February 15, 2022Assignee: Tulai Therapeutics, Inc.Inventors: Corinne Bright, Kondapavulur T. Venkateswara-Rao, Emily Stein
-
Patent number: 11202762Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.Type: GrantFiled: November 4, 2020Date of Patent: December 21, 2021Assignee: DSM IP ASSETS B.V.Inventors: George Mihov, Guy Draaisma, Silvana Rensina Antonnietta Di Silvestre, Tristan Handels
-
Patent number: 11166947Abstract: The present invention generally relates to treating attention-deficit disorders (e.g., ADHD) by providing an effective amount of an ADHD-effective agent to a patient in need thereof (e.g., a child).Type: GrantFiled: October 31, 2017Date of Patent: November 9, 2021Assignee: Neos Therapeutics, LPInventors: Mark Tengler, Nathan Teuscher
-
Patent number: 11147904Abstract: An implantable medical device including at least one double-walled microsphere containing an active agent, and a biodegradable polymer layer containing the at least one double-walled microsphere.Type: GrantFiled: August 4, 2017Date of Patent: October 19, 2021Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: Lauren Elizabeth Kokai, Kacey Gribbin Marra
-
Patent number: 11135167Abstract: Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.Type: GrantFiled: July 19, 2019Date of Patent: October 5, 2021Assignee: Terumo CorporationInventors: Gregory M. Cruise, Gloria Hincapie, Clayton Harris
-
Patent number: 11118016Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.Type: GrantFiled: August 26, 2020Date of Patent: September 14, 2021Assignee: Starpharma Pty Ltd.Inventors: David Owen, Brian Devlin Kelly
-
Patent number: 11083802Abstract: Implantable materials visible under ultrasound may delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.Type: GrantFiled: March 12, 2020Date of Patent: August 10, 2021Assignee: Incept, LLCInventors: Patrick Campbell, Amarpreet S. Sawhney
-
Patent number: 11052053Abstract: A nanoparticle includes a core. The core includes a bio-resorbable polyester and a hydrophilic polymer. The hydrophilic polymer is a portion of the bio-resorbable polyester or a separate polymer. An acylated human lactoferrin-derived peptide is coated onto the core. The acylated human lactoferrin-derived peptide is a peptide with the amino acid sequence SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR or an amino acid sequence, which does not differ by more than 8 amino acid positions from the sequence SEQ ID NO: 1. The N-terminus of the human lactoferrin-derived peptide is acylated with a C16-monoacyl group.Type: GrantFiled: April 24, 2019Date of Patent: July 6, 2021Assignee: Evonik Operations GmbHInventors: Roland Brock, Rike Nabbefeld, Silko Grimm, Anne Benedikt, Andrea Engel, Alexander Henrik Baron van Asbeck, Jürgen Dieker
-
Patent number: 10966955Abstract: Disclosed herein is an ocular drug delivery system, comprising a positively charged chitosan-modified hydrogel, a secretory phospholipase A2 (sPLA2) hydrolysable liposome encapsulating an anti-inflammatory drug and having a negative surface charge, a first thiolated hyaluronic acid (HA-SH) nanoparticle encapsulating a wound-healing drug and having a negative surface charge, and a second HA-SH nanoparticle encapsulating a transforming growth factor-? inhibitor and having a negative surface charge. The sPLA2 hydrolysable liposome and the first and second HA-SH nanoparticles are attached to the positively charged chitosan-modified hydrogel by electrostatic attraction. Uses of the system are also disclosed.Type: GrantFiled: March 13, 2020Date of Patent: April 6, 2021Assignee: Chang Gung UniversityInventors: Jui-Yang Lai, Li-Jyuan Luo, Chung-Cheng Lo, Duc Dung Nguyen
-
Patent number: 10955419Abstract: Methods, systems, compositions and kits are provided for the analysis of target molecules using chromophoric polymer dots conjugated to biomolecules. The use of chromophoric polymer dots improves detection sensitivity and stability when compared with existing techniques. In some aspects, methods, systems, and kits are provided for detecting a target protein using chromophoric polymer dots conjugated to biomolecules in a Western blot analysis. Related methods, systems, compositions and kits are also provided.Type: GrantFiled: March 5, 2014Date of Patent: March 23, 2021Assignee: University of WashingtonInventor: Daniel T. Chiu
-
Patent number: 10940119Abstract: In one aspect, methods of preparing composite nanoparticle compositions are described herein. For example, in some embodiments, a method comprises providing a zein solution stream, an organic fluid stream including at least one additive and at least one buffer fluid stream. The zein solution stream, organic fluid stream and buffer fluid stream are delivered to a chamber for mixing at one or more rates sufficient to flash precipitate composite nanoparticles including the additive encapsulated by a shell comprising the zein.Type: GrantFiled: August 8, 2016Date of Patent: March 9, 2021Assignee: The Trustees of Princeton UniversityInventors: Nikolas T. Weissmueller, Robert K. Prud'Homme
-
Patent number: 10925883Abstract: Embodiments of the present invention are directed to a plurality of substantially spherical microspheres comprising at least one API substantially dispersed in at least one polymer and a lyoprotectant on an outside surface of the plurality of substantially spherical microspheres, wherein the plurality of substantially spherical microspheres have a D99[num] particle diameter of less than about 10 m; a D90[num] circularity value of from about 0.8 to about 1.0; and comprise API in a weight of about 20 to about 40 wt. % of the polymer. Other embodiments relate to injectable compositions comprising such microspheres and methods of treating a number of conditions by administering such injectable compositions to a subject.Type: GrantFiled: October 28, 2016Date of Patent: February 23, 2021Assignee: SpineTheraInventors: Jeffrey Missling, Emily R. Rolfes Meyering, Henry Meyer, Celeste Ondich
-
Patent number: 10881609Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.Type: GrantFiled: September 5, 2019Date of Patent: January 5, 2021Assignee: Retina Foundation Of The SouthwestInventor: Karl Csaky
-
Patent number: 10774122Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.Type: GrantFiled: March 19, 2018Date of Patent: September 15, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Arul Chinnaiyan, Xiaoju Wang
-
Patent number: 10729702Abstract: Provided is a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol encapsulated in a biodegradable polymer to control the release of the oxysterol. Methods of making and use are further provided.Type: GrantFiled: June 6, 2019Date of Patent: August 4, 2020Assignee: Warsaw Orthopedic, Inc.Inventors: David S. Scher, Benjamin T. Reves, Roger E. Harrington, Susan J. Drapeau, Jerbrena C. Jacobs
-
Patent number: 10583091Abstract: This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.Type: GrantFiled: October 23, 2015Date of Patent: March 10, 2020Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard CollegeInventors: Jinjun Shi, Xi Zhu, Omid C. Farokhzad, Xiaoding Xu, Yanlan Liu, Aude Thiriot, Ulrich Von Andrian
-
Patent number: 10577554Abstract: Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.Type: GrantFiled: March 14, 2014Date of Patent: March 3, 2020Assignee: Children's Medical Center CorporationInventors: John Kheir, Brian D. Polizzotti
-
Patent number: 10517934Abstract: Compositions and methods for the treatment of skin disorders or disease are provided.Type: GrantFiled: August 20, 2015Date of Patent: December 31, 2019Assignee: ProTransit Nanotherapy, LLCInventor: Vinod D. Labhasetwar
-
Patent number: 10517910Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.Type: GrantFiled: June 17, 2016Date of Patent: December 31, 2019Assignee: SILLAJEN, INC.Inventors: Tae Ho Hwang, Nam Hee Lee, Mong Cho, Ungbae Jeon, Doo Jin Byun
-
Patent number: 10463735Abstract: The present disclosure concerns a digital corneal crosslinking technology for adjusting the corneal curvature, comprising the following steps: administering in drops a composition comprising a photoinitiator compound to the corneal stromal of the subject, locally irradiating the corneal by utilizing digital micromirror device controlled by computer. The corneal curvature can be adjusted totally or locally. The invention also discloses an apparatus for the digital corneal crosslinking. The method and apparatus is minimum invasive and can be used to accurately and efficiently adjust the corneal curvature.Type: GrantFiled: November 15, 2016Date of Patent: November 5, 2019Assignee: ZHEJIANG UNIVERSITYInventors: Tao Xie, Jingjun Wu, Qian Zhao, Limei Huang
-
Patent number: 10446782Abstract: A quantum dot device includes a first electrode and a second electrode facing each other, a quantum dot layer disposed between the first electrode and the second electrode and comprising a plurality of quantum dots, a first charge auxiliary layer disposed between the first electrode and the quantum dot layer and contacting the quantum dot layer, and a second charge auxiliary layer disposed between the second electrode and the quantum dot layer and contacting the quantum dot layer, wherein the plurality of quantum dots includes a quantum dot including an organic ligand on a surface thereof, the organic ligand including a hydrophilic functional group at a terminal end.Type: GrantFiled: August 20, 2018Date of Patent: October 15, 2019Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Moon Gyu Han, Dae Young Chung, Hongkyu Seo, Kwanghee Kim, Kun Su Park, Sujin Park, Eun Joo Jang
-
Patent number: 10434048Abstract: A topical sunscreen composition includes metal oxide sunscreen particles, polylactic acid, and a cosmetic carrier in which the metal oxide sunscreen particles and polylactic acid are dispersed. A method of preparing a topical sunscreen composition includes dispersing metal oxide sunscreen particles and polylactic acid in a cosmetic carrier. A method of protecting human skin from ultraviolet (UV) radiation includes applying to human skin a topical sunscreen composition including metal oxide sunscreen particles and polylactic acid dispersed in a cosmetic carrier.Type: GrantFiled: October 19, 2017Date of Patent: October 8, 2019Assignee: CYBERDERM LABORATORIES INC.Inventors: Denis Dudley, Thomas Heinar, Sara Dudley
-
Patent number: 10369537Abstract: This present invention provides a spray dryer for use in preparing particles for inhalation, the spray dryer comprising a multi-nozzle apparatus comprising multiple single nozzles suitable for use in preparing inhalation powders and with a drying gas flow rate greater than about 80 kg/h. Also provided is a method for scaling-up a spray drying process for preparing particles for inhalation from a smaller scale spray dryer to a larger scale spray dryer, relative in size to each other, the method comprising the use in the larger scale spray dryer of a multi-nozzle apparatus comprising single nozzles suitable for use in preparing inhalation powders, wherein the number of nozzles in the larger spray dryer is determined by the ratio of the drying gas flow rate of the larger scale spray dryer to the drying gas flow rate of the smaller scale spray dryer.Type: GrantFiled: September 29, 2016Date of Patent: August 6, 2019Assignee: Hovione Holding LimitedInventors: José Luis Santos, Luis Olival, Maria Palha, Filipa Maia, Filipe Neves
-
Patent number: 10369113Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.Type: GrantFiled: July 13, 2016Date of Patent: August 6, 2019Assignee: The Johns Hopkins UniversityInventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
-
Patent number: 10364474Abstract: Disclosed are methods for identifying and/or classifying microbes using one or more single nucleotide polymorphisms (SNPs) in 16S ribosomal RNA (16S rRNA) of prokaryotes and/or one or more SNPs in 5.8S ribosomal RNA (5.8S rRNA) of eukaryotes. Also disclosed are probes, primers and kits that are useful in those methods. Methods for the diagnosis of sepsis based upon these SNPs are also disclosed.Type: GrantFiled: May 29, 2014Date of Patent: July 30, 2019Assignee: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Flavia Huygens
-
Patent number: 10350222Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.Type: GrantFiled: January 31, 2017Date of Patent: July 16, 2019Assignee: SpineTheraInventor: Jeffrey Missling
-
Patent number: 10328033Abstract: A nanostructured biocompatible wafer for drug delivery to a tissue. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of polymer fibers. Also provided is a method for treating an ocular surface disease, disorder, or infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.Type: GrantFiled: April 3, 2018Date of Patent: June 25, 2019Assignee: Integral BioSystems LLCInventors: Shikha P. Barman, Moli Liu, Koushik Barman, Kevin L. Ward, Brendan Hackett
-
Patent number: 10307373Abstract: Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.Type: GrantFiled: February 8, 2011Date of Patent: June 4, 2019Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Moon Suk Kim, Da Yeon Kim
-
Patent number: 10293044Abstract: Disclosed are compositions, kits, and methods for improving feed conversion rate in an animal in need thereof. The methods typically comprise administering orally to the animal a composition comprising biodegradable particles, the biodegradable particles comprising a polymer or a co-polymer comprising polylactide (PLA) and having an effective average diameter of 0.5-5 ?m. In the methods, the animal is administered a dose of the biodegradable particles that is effective for improving feed conversion rate in the animal in comparison to an animal that is not administered the composition.Type: GrantFiled: October 24, 2016Date of Patent: May 21, 2019Assignee: Auburn UniversityInventors: Bernhard Kaltenboeck, Ram B. Gupta, Erfan U. Chowdhury, Courtney A. Ober
-
Patent number: 10285939Abstract: The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.Type: GrantFiled: September 17, 2014Date of Patent: May 14, 2019Assignee: Eberhard Karls Universität Tübingen Medizinische FakultätInventors: Andreas Herrmann, Jan Willem De Vries, Martin Stephan Spitzer, Sven Oliver Schnichels
-
Patent number: 10286033Abstract: The invention provides methods and compositions for use of desmopressin in combination with an alpha-adrenergic receptor antagonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: GrantFiled: November 19, 2015Date of Patent: May 14, 2019Assignee: Serenity Pharmaceuticals, LLCInventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
-
Patent number: 10258563Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.Type: GrantFiled: April 20, 2010Date of Patent: April 16, 2019Assignee: Drexel UniversityInventors: Steven P. Wrenn, Stephen Dicker
-
Patent number: 10231937Abstract: An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.Type: GrantFiled: June 16, 2015Date of Patent: March 19, 2019Assignee: The Trustees of Princeton UniversityInventors: Robert F. Pagels, Robert K. Prud'homme
-
Patent number: 10221272Abstract: A method of forming a patterned polymer layer on a substrate and a substrate having a polymer layer formed by the method. The method includes providing a substrate comprising a first surface having a first surface energy and a pattern located on the substrate forming a second surface having a second, lower surface energy than the first surface, and selectively depositing a polymeric layer onto the first surface using a monomer material in an initiated chemical vapor deposition process, wherein the initiated chemical vapor deposition process is operated under supersaturation conditions during the deposition process.Type: GrantFiled: June 5, 2017Date of Patent: March 5, 2019Assignee: DREXEL UNIVERSITYInventors: Kenneth Ka Shun Lau, Sruthi Janakiraman, Chia-Yun Hsieh
-
Patent number: 10195309Abstract: A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.Type: GrantFiled: February 1, 2008Date of Patent: February 5, 2019Assignee: LOCATE THERAPEUTICS LIMITEDInventors: Patrick Ginty, Robin Andrew Quirk, Kevin Morris Shakesheff
-
Patent number: 10188658Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.Type: GrantFiled: September 25, 2015Date of Patent: January 29, 2019Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Damon Jude Wischik, John Mervyn David Storey, Charles Robert Harrington
-
Patent number: 10179190Abstract: Methods of treating tissue of a patient, e.g., tissue of an organ such that the bladder, are described. The methods may comprise inserting a medical device within the bladder; and injecting a composition to separate a first layer of tissue from a second layer of tissue. The composition may comprise at least one polysaccharide compound having a concentration ranging from approximately 0.05% to approximately 25% by weight, with respect to the total weight of the composition. The composition may at least partially separate the first layer of tissue from the second layer of tissue. At least one of the first layer of tissue or the second layer of tissue may be a detrusor muscle tissue.Type: GrantFiled: May 27, 2016Date of Patent: January 15, 2019Assignee: Boston Scientific Scimed, Inc.Inventors: Sandra Nagale, David Shreeve, Mark Boden, Jonathan Zoll, Timothy Harrah, Steven Kangas, Kasyap Seethamraju, Deanna Cavallaro, Martin Phelan
-
Patent number: 10179834Abstract: The disclosure relates to biodegradable polyether network polymers crosslinked via ester linkages, to substrates, implants and scaffolds comprising the biodegradable polyether network polymers, to methods for preparing such network polymers, implants and scaffolds, and to methods of using substrates, implants and scaffolds comprising the network polymers, particularly for culturing cells and regenerating tissue.Type: GrantFiled: April 10, 2014Date of Patent: January 15, 2019Assignee: The University of MelbourneInventors: Anton Blencowe, Berkay Ozcelik, Greg Guanghua Qiao
-
Patent number: 10159743Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.Type: GrantFiled: March 12, 2013Date of Patent: December 25, 2018Assignee: The Johns Hopkins UniversityInventors: Jie Fu, Peter A. Campochiaro, Justin Scot Hanes
-
Patent number: 10137088Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.Type: GrantFiled: August 19, 2016Date of Patent: November 27, 2018Assignee: Pfizer Inc.Inventors: Stephen E. Zale, Kevin Andrew McDonnell, Allen Thomas Horhota
-
Patent number: 10076496Abstract: The present invention provides organic nanoparticles that include a molecule having a Log P value of about 3 or above, an amphiphilic diblock copolymer or a surfactant, and a pharmaceutically-acceptable hydrophilic polymer. The present invention also provides methods of making these nanoparticles, e.g., by flash nanoprecipitation, with control over particle size and surface properties. The methods of the present invention provide a means for co-precipitating a water-insoluble compound with an amphiphilic stabilizer within a few milliseconds. The nanoparticles of the present invention exhibit high drug loading, e.g., 50% w/w, and can be produced with a mean particle size less than 200 nm and with a narrow particle size distribution.Type: GrantFiled: November 9, 2012Date of Patent: September 18, 2018Assignee: The Chinese University of Hong KongInventors: Albert Hee Lum Chow, Shing Fung Chow, Xin Ran Zhang, Ka Yee Wan, Kwok Kin Cheng, Lawrence William Baum
-
Patent number: 10064819Abstract: Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.Type: GrantFiled: July 6, 2012Date of Patent: September 4, 2018Assignee: University of Utah Research FoundationInventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Patent number: 10004790Abstract: A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.Type: GrantFiled: October 5, 2015Date of Patent: June 26, 2018Assignee: THE CORPORATION OF MERCER UNIVERSITYInventor: Martin J. D'Souza
-
Patent number: 9919052Abstract: Polyurethane microparticles are derived from structural units comprising poly(alkylene oxide) moieties, caprolactone moieties and urethane moieties. The microparticles may include an active agent and have a particle size from 0.1 to 100 microns. Microparticles for injection have a particle size of 15 to 80 microns; for use as a aerosol 1 to 3 microns; and for intraocular use 0.02 to 2 microns. Dispersivity is in the range 1 to 3.Type: GrantFiled: June 20, 2012Date of Patent: March 20, 2018Assignee: Ferring B.V.Inventors: Alistair Ross, Jennifer S. Law, Fiona E. McInnes
-
Patent number: 9885808Abstract: Coating with photochromic properties, method for producing said coating and use thereof applicable to optical articles and glazed surfaces. The coating is formed by the combination of the following three elements: (1) a polymeric matrix, which is typically rigid and deposited on the surface of interest; (2) hollow, sealed micro- and/or nanocapsules dispersed within said matrix; and (3) solutions of photochromic compounds (chosen from a group comprising spirooxazine, azobenzenes or chromenes) in a liquid solvent that does not react (with the photochromic compound and with the capsule wall), which are encapsulated inside said micro- or nanocapsules.Type: GrantFiled: March 5, 2013Date of Patent: February 6, 2018Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS(CSIC)Inventors: Jordi Hernando Campos, Claudio Roscini, Nuria Alexandra Vazquez Mera, Daniel Ruiz Molina